Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 2/20 | 0.49 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050283 | 1.00 | POLG (0.50) | POLGPOLBPNPFUT5P2RY2 | |
| SCHEMBL21050234 | 0.92 | POLG (0.50) | POLGPOLBPNPFUT5P2RY2 | |
| SCHEMBL21050275 | 0.92 | POLG (0.50) | POLGPOLBPNPFUT5P2RY2 | |
| SCHEMBL21100151 | 0.87 | POLG (0.53) | POLGPOLBPNPFUT5P2RY2 | |
| SCHEMBL21050300 | 0.83 | ADORA3 (0.56) | PNPHPRT1ADORA3 | |
| SCHEMBL21050279 | 0.83 | ADORA3 (0.56) | PNPHPRT1ADORA3 | |
| SCHEMBL22107793 | 0.81 | POLG (0.49) | POLGPOLBPNPFUT5P2RY2 | |
| SCHEMBL22110588 | 0.79 | POLG (0.54) | POLGPOLBPNPFUT5P2RY2 | |
| SCHEMBL23358376 | 0.79 | POLG (0.59) | POLGPOLBPNPFUT5P2RY2 | |
| Phosphoric Acid SCHEMBL21050293 | 0.79 | PNP (0.52) | POLBPNPHPRT1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | claimed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | SAMHD1, POLRMT, RNGTT | POLG 73/4885POLB 8/4885PNP 20/4885 |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SAMHD1, POLRMT, RNGTT | POLG 73/4885POLB 8/4885PNP 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.